US · TAK
Takeda Pharmaceutical Company Limited
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Tokyo 103-8668
- Website
- takeda.com
Price · as of 2025-03-31
$16.62
Market cap 59.23B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $0.20 | -98.8% |
| Intrinsic Value(DCF) | $5.98 | -64.02% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $3.40 | -79.54% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $21.16 | $25.76 | $3.88 | $4.20 | $5.30 |
| 2012 | $19.75 | $25.95 | $3.09 | $0.00 | $7.50 |
| 2013 | $21.11 | $25.42 | $1.52 | $0.00 | $6.20 |
| 2014 | $21.66 | $23.19 | $3.64 | $0.20 | $7.40 |
| 2015 | $22.50 | $20.80 | $1.52 | $0.00 | $0.00 |
| 2016 | $19.66 | $21.42 | $2.28 | $0.00 | $3.30 |
| 2017 | $23.67 | $23.41 | $3.60 | $0.00 | $2.00 |
| 2018 | $18.24 | $25.28 | $2.45 | $0.00 | $8.20 |
| 2019 | $16.02 | $22.83 | $6.67 | $0.00 | $9.80 |
| 2020 | $17.39 | $21.47 | $51.10 | $0.00 | $6.00 |
| 2021 | $16.11 | $24.17 | $35.72 | $0.00 | $4.40 |
| 2022 | $12.54 | $22.20 | $19.41 | $0.00 | $9.50 |
| 2023 | $15.18 | $23.48 | $1.78 | $0.00 | $13.90 |
| 2024 | $12.87 | $20.70 | $0.00 | $0.00 | $4.20 |
| 2025 | $14.96 | $22.65 | $0.00 | $0.00 | $3.40 |
AI valuation
Our deep-learning model estimates Takeda Pharmaceutical Company Limited's (TAK) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $0.20
- Current price
- $16.62
- AI upside
- -98.8%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$5.98
-64.02% upside
Graham-Dodd
—
— upside
Graham Formula
$3.40
-79.54% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| TAK | Takeda Pharmaceutical Com… | $16.62 | 59.23B | +36% | -64% | — | -80% | 66.53 | 1.04 | 1.57 | 9.33 | — | -3.55 | 65.51% | 7.48% | 2.36% | 1.52% | 1.87% | 0.74% | 0.65 | 2.49 | 1.01 | 0.45 | 3.41 | -2624.00% | 745.00% | 26347.00% | 11.93% | 0.42 | 7.55% | 4.21% | 280.30% | 8.50% | 32.96 | 13.18 | 2.46 | 1.11 |
| A | Agilent Technologies, Inc… | $121.38 | 34.41B | -21% | -48% | -87% | -44% | 96.67 | 6.22 | 6.04 | 23.72 | 3059.02 | 23.01 | 52.43% | 21.29% | 18.75% | 6.87% | 16.33% | 3.53% | 0.50 | 13.21 | 1.96 | 1.40 | 0.85 | 316.00% | 673.00% | -1610.00% | 2.75% | 0.66 | 14.01% | 0.67% | 65.00% | 3.31% | 29.43 | 37.78 | 6.26 | 5.50 |
| ALC | Alcon Inc. | $87.18 | 42.49B | -32% | -61% | -65% | -71% | 42.77 | 1.90 | 4.03 | 19.38 | — | 11.11 | 55.24% | 13.08% | 9.42% | 4.50% | 4.55% | 3.17% | 0.24 | — | 2.12 | 1.16 | 1.58 | -341.00% | 494.00% | 2281.00% | 4.12% | 0.74 | 6.84% | 0.40% | 16.90% | 2.12% | 33.49 | 26.36 | 4.38 | 3.24 |
| BDX | Becton, Dickinson and Com… | $176.48 | 63.94B | +10% | -66% | — | -47% | 25.90 | 1.71 | 1.99 | 12.47 | — | -4.09 | 45.44% | 11.80% | 7.68% | 6.54% | 5.17% | 2.98% | 0.76 | 4.21 | 1.11 | 0.46 | 3.70 | -51.00% | 823.00% | -1309.00% | 6.14% | 0.41 | 6.01% | 2.75% | 71.30% | 8.27% | 23.97 | 23.14 | 2.83 | 1.86 |
| CAH | Cardinal Health, Inc. | $229.23 | 53.94B | -51% | +121% | — | -82% | 22.84 | -12.89 | 0.16 | 13.30 | 26.27 | -2.40 | 3.67% | 1.02% | 0.70% | -52.35% | -7229.54% | 3.19% | -3.36 | 10.58 | 0.94 | 0.44 | 1.76 | 8696.00% | -187.00% | -4309.00% | 5.16% | 0.06 | -7872.34% | 1.38% | 31.50% | 3.51% | 18.16 | 22.33 | 0.19 | 4.68 |
| EW | Edwards Lifesciences Corp… | $86.47 | 50.77B | -6% | -55% | -72% | -59% | 47.67 | 4.93 | 8.40 | 33.68 | — | 6.85 | 78.13% | 26.97% | 17.69% | 10.52% | 19.08% | 7.99% | 0.01 | — | 3.72 | 2.12 | -1.98 | -7374.00% | 1155.00% | 36050.00% | 2.62% | 0.88 | 18.76% | 0.00% | 0.00% | 2.71% | 29.43 | 36.07 | 7.94 | 11.83 |
| HLN | Haleon plc | $11.07 | 49.3B | +256% | -54% | — | -81% | 22.30 | 2.22 | 3.37 | 15.73 | 178.37 | -3.96 | 64.77% | 22.44% | 15.11% | 10.01% | 7.93% | 4.88% | 0.52 | 7.28 | 0.92 | 0.70 | 2.62 | 1250.00% | -396.00% | -391.00% | 5.42% | 0.46 | 8.27% | 1.65% | 36.70% | 5.15% | 18.02 | 22.14 | 4.04 | 3.11 |
| INSM | Insmed Incorporated | $149.33 | 31.85B | -50% | +3,425% | — | — | -24.48 | 42.30 | 51.55 | -26.12 | -162.35 | 61.87 | 79.41% | -194.04% | -210.54% | -249.28% | -969.45% | -59.53% | 1.04 | -14.04 | 3.83 | 3.35 | -0.22 | 1508.00% | 6673.00% | 3709.00% | -3.10% | -1.99 | -797.14% | 0.00% | 0.00% | 1.60% | -26.00 | -31.62 | 50.46 | 8.06 |
| IQV | IQVIA Holdings Inc. | $178.81 | 30.45B | -2% | -53% | — | -39% | 22.01 | 4.61 | 1.84 | 12.70 | 471.04 | -1.99 | 26.28% | 14.02% | 8.34% | 21.65% | 9.92% | 4.79% | 2.49 | 3.14 | 0.75 | 0.67 | 4.10 | 467.00% | 587.00% | -298.00% | 6.85% | 0.32 | 10.54% | 0.00% | 0.00% | 4.15% | 19.23 | 21.45 | 2.70 | 1.83 |
| RMD | ResMed Inc. | $256.26 | 37.41B | -10% | -40% | -86% | -35% | 28.88 | 6.78 | 7.86 | 20.96 | 77.17 | 16.47 | 59.36% | 32.75% | 27.22% | 25.86% | 25.33% | 18.62% | 0.14 | 133.66 | 3.44 | 2.16 | -0.19 | 3743.00% | 984.00% | 2918.00% | 4.11% | 1.72 | 29.91% | 0.77% | 22.20% | 3.96% | 23.79 | 24.13 | 7.79 | 13.72 |
| VEEV | Veeva Systems Inc. | $182.01 | 29.92B | +3% | +13% | -70% | -43% | 49.42 | 6.05 | 12.85 | 41.34 | 144.65 | 6.60 | 74.53% | 25.17% | 26.00% | 13.63% | 75.08% | 10.78% | 0.01 | — | 4.51 | 4.44 | -1.43 | 3416.00% | 1620.00% | 2083.00% | 3.03% | 0.78 | 149.51% | 0.00% | 0.00% | 1.12% | 43.70 | 28.25 | 11.00 | 16.19 |
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
- CEO
- Christophe Weber
- Employees
- 49.28K
- Beta
- 0.08
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($5.98 ÷ $16.62) − 1 = -64.02% (DCF, example).